ADP 027
Alternative Names: ADP-027Latest Information Update: 11 Mar 2024
At a glance
- Originator Alector
 - Class Antiparkinsonians
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Preclinical Parkinson's disease
 
Most Recent Events
- 31 Dec 2023 Alector has patent protection for more than 20 targets and/or technologies before December 2023
 - 31 Dec 2023 Alector has patents pending for more than 20 targets and/or technologies before December 2023
 - 31 Dec 2023 Preclinical trials in Parkinson's disease in USA (unspecified route) before December 2023